合成,生物活性评估,分子对接和ADMET研究的新染色体同源表现出强大的抗癌活性
Heba M Abo-Salem1, Sahar S M El Souda2, Heba I Shafey3
1Chemistry of Natural Compounds Department, National Research Centre, Dokki, Giza, 12622, Egypt. hb_abosalem@yahoo.com.
Scientific reports
|April 26, 2024
概括
新的克罗曼衍生物对乳腺癌和结肠癌细胞系具有显著的抗癌活性. 这些化合物诱导DNA分裂和亡,提供潜在的新治疗策略.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 染色体表现出有希望的治疗和抗癌特性.
- 开发新的抗癌药物对于有效的癌症治疗至关重要.
研究的目的:
- 合成和评估针对各种癌症细胞系的新克罗曼衍生物的细胞毒性活性.
- 阐明最强效化合物的作用机制.
主要方法:
- 通过对6-formyl-7-hydroxy-5-methoxy-2-methylchromone与活性有机化合物的反应合成chromanone衍生物.
- 对MCF-7,HCT-116,HepG2和BJ1细胞系进行细胞毒性测定.
- 诱导亡,细胞周期分析,基因表达研究 (CDK4,BCL-2,P53,BAX) 和分子对接.
主要成果:
- 化合物14b,17和19对人类乳腺癌 (MCF-7) 细胞表现出显著的细胞毒性.
- 化合物6a,6b,11和14c对结肠癌 (HCT-116) 细胞系表现出强烈的活性.
- 这些化合物诱导了DNA碎片化,调节了与亡相关的基因表达,并导致细胞循环停止. 化合物14b和14c表现出一种双重机制.
- 对接研究证实了活性化合物与CDK4酶的强烈结合亲和力.
结论:
- 合成的克罗曼衍生物具有显著的细胞毒性和抗癌潜力.
- 该机制涉及诱导亡,细胞循环停止和关键调节基因的调节.
- 这些发现支持开发chromanone衍生物作为针对CDK4.4的新型抗癌疗法.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
708
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
708
01:26Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K